Route 92 Tenzing 7 Delivery Catheter Studied for Neurovascular Interventions

November 14, 2023—Route 92 Medical, a California-based medical technology company focused on neurovascular interventions, announced the publication of results from a multicenter clinical study evaluating the efficacy, safety, and efficiency of the company’s Tenzing 7 delivery catheter in delivering therapeutic devices for mechanical thrombectomy in acute ischemic strokes.

As outlined in the company’s press release, key findings from the study include the following:

• 95.9% delivery of large-bore reperfusion catheters to the clot face powered by a Tenzing 7 delivery catheter without needing a stent-retriever to anchor.
• 94.9% of patients achieved recanalization.
• 54.2% of patients achieved first-pass reperfusion with a 07-sized aspiration catheter, which compares favorably with the best stent retriever data including with the use of balloon guides.
• At hospital discharge, patients experienced a significant median National Institutes of Health Stroke Scale improvement of 10.
• 41.0% of patients achieved a good 90-day functional outcome.

Daniel A. Tonetti, MD, et al published the findings in Stroke: Vascular and Interventional Neurology.

“Early clinical and in vitro experiences have always shown the potential of the Tenzing 7 delivery catheter,” commented Dr. Tonetti in the Route 92 press release. “These multicenter results support its position as a game-changer in the field of neurointervention.” Dr. Tonetti is Director, Acute Stroke and Neurointerventional Suite at Cooper University Health Care in Camden, New Jersey.